Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New Upgrade: Dedicated Screeners for Stocks & ETFs

Optimi Health Corp.

Contributing Author

Recent Articles by Optimi Health Corp.

Oct-26	Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity OPTH GlobeNewswire
Oct-20	Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia OPTH GlobeNewswire
Oct-07	Optimi Health to Present at the ThinkEquity Conference OPTH GlobeNewswire
Sep-29	Optimi Health Appoints Melanie Pump to Board of Directors OPTH GlobeNewswire
Sep-23	Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply OPTH GlobeNewswire
Sep-22	Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer OPTH GlobeNewswire
Sep-16	Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder OPTH GlobeNewswire
Sep-10	Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder OPTH GlobeNewswire
Sep-08	Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference OPTH GlobeNewswire
Aug-14	Optimi Health Establishes Discretionary Equity Facility OPTH GlobeNewswire
Jun-29	Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression OPTH +8.80% GlobeNewswire
Jun-10	Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial OPTH GlobeNewswire
Jun-08	Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development OPTH +11.21% GlobeNewswire
Jun-02	Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia OPTH GlobeNewswire
May-29	Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia OPTH +5.58% GlobeNewswire

Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)